The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $117.55

Today's change0.00 0.00%
Updated October 18 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $117.55

Today's change0.00 0.00%
Updated October 18 4:00 PM EDT. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc closed at (U.S.)$117.55.

Shares have lost 5.85% over the last five days, but have gained 213.97% over the last year to date. This security has outperformed the S&P 500 by 189.07% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $117.55
  • High--
  • Low--
  • Bid / Ask(U.S.) $98.30 / (U.S.) $127.00
  • YTD % change+213.97%
  • Volume0
  • Average volume (10-day)868,481
  • Average volume (1-month)1,938,894
  • Average volume (3-month)1,186,555
  • 52-week range(U.S.) $31.38 to (U.S.) $126.16
  • Beta2.96
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.12
Updated October 18 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-670.81%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.22%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue16191714
Total other revenue--------
Total revenue16191714
Gross profit--------
Total cost of revenue--------
Total operating expense136125133120
Selling / general / administrative46382822
Research & development918710598
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-120-107-115-107
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-118-107-113-104
Income after tax-118-107-113-104
Income tax, total----0--
Net income-118-107-113-104
Total adjustments to net income--------
Net income before extra. items-118-107-113-104
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-118-107-113-104
Inc. avail. to common incl. extra. items-118-107-113-104
Diluted net income-118-107-113-104
Dilution adjustment--------
Diluted weighted average shares88868686
Diluted EPS excluding extraordinary itemsvalue per share-1.34-1.25-1.32-1.21
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.34-1.25-1.32-1.21